Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 912-917

  Mori, Shuuichi ^a   Shigemoto, Kazuhiro ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Experimental animal model; IgG4 subclass; Muscle specific kinase; Myasthenia gravis; Neuromuscular junction

Indexed keywords

ANTIBODY; CHOLINESTERASE INHIBITOR; MUSCLE SPECIFIC KINASE ANTIBODY; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATHOGENICITY; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; PROTEIN EXPRESSION; REVIEW;

ANIMALS; AUTOANTIBODIES; HUMANS; IMMUNOGLOBULIN G; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SYNAPTIC MEMBRANES;

EID: 84879191215     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.005     Document Type: Review

References (77)

1. Lang B., Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2003, 2:94-100.
2. Vincent A., Lang B., Kleopa K.A. Autoimmune channelopathies and related neurological disorders. Neuron 2006, 52:123-138.
3. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 2006, 116:2843-2854.
4. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol 2007, 26:5-10.
5. Nussinovitch U., Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev 2012, 11:A377-A385.
6. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
7. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun. Rev 2013, 12(9):931-935. (this issue).
8. Ganju P., Walls E., Brennan J., Reith A.D. Cloning and developmental expression of Nsk2, a novel receptor tyrosine kinase implicated in skeletal myogenesis. Oncogene 1995, 11:281-290.
9. Valenzuela D.M., Stitt T.N., DiStefano P.S., Rojas E., Mattsson K., Compton D.L., et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 1995, 15:573-584.
10. DeChiara T.M., Bowen D.C., Valenzuela D.M., Simmons M.V., Poueymirou W.T., Thomas S., et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 1996, 85:501-512.
11. Weatherbee S.D., Anderson K.V., Niswander L.A. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006, 133:4993-5000.
12. Kim N., Stiegler A.L., Cameron T.O., Hallock P.T., Gomez A.M., Huang J.H., et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008, 135:334-342.
13. Zhang B., Luo S., Wang Q., Suzuki T., Xiong W.C., Mei L. LRP4 serves as a coreceptor of agrin. Neuron 2008, 60:285-297.
14. Wu H., Xiong W.C., Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. Development 2010, 137:1017-1033.
15. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
16. Sanders D.B., El-Salem K., Massey J.M., McConville J., Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003, 60:1978-1980.
17. Bartoccioni E., Scuderi F., Minicuci G.M., Marino M., Ciaraffa F., Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006, 67:505-507.
18. Deymeer F., Gungor-Tuncer O., Yilmaz V., Parman Y., Serdaroglu P., Ozdemir C., et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007, 68:609-611.
19. Ohta K., Shigemoto K., Fujinami A., Maruyama N., Konishi T., Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 2007, 14:1029-1034.
20. Evoli A., Bianchi M.R., Riso R., Minicuci G.M., Batocchi A.P., Servidei S., et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008, 1132:76-83.
21. Wolfe G.I., Oh S.J. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann N Y Acad Sci 2008, 1132:71-75.
22. Oh S.J. Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol 2009, 5:53-64.
23. Pasnoor M., Wolfe G.I., Nations S., Trivedi J., Barohn R.J., Herbelin L., et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010, 41:370-374.
24. Meyer A., Levy Y. Geoepidemiology of myasthenia gravis [corrected]. Autoimmun Rev 2010, 9:A383-A386.
25. Lindstrom J. Is "seronegative" MG explained by autoantibodies to MuSK?. Neurology 2004, 62:1920-1921.
26. Selcen D., Fukuda T., Shen X.M., Engel A.G. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 2004, 62:1945-1950.
27. Shigemoto K., Kubo S., Maruyama N., Hato N., Yamada H., Jie C., et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006, 116:1016-1024.
28. Jha S., Xu K., Maruta T., Oshima M., Mosier D.R., Atassi M.Z., et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 2006, 175:107-117.
29. Shigemoto K., Kubo S., Jie C., Hato N., Abe Y., Ueda N., et al. Myasthenia gravis experimentally induced with muscle-specific kinase. Ann N Y Acad Sci 2008, 1132:93-98.
30. Richman D.P., Nishi K., Morell S.W., Chang J.M., Ferns M.J., Wollmann R.L., et al. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol 2012, 69:453-460.
31. Cole R.N., Reddel S.W., Gervasio O.L., Phillips W.D. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008, 63:782-789.
32. Meriggioli M.N., Sanders D.B. Muscle autoantibodies in myasthenia gravis: beyond diagnosis?. Expert Rev Clin Immunol 2012, 8:427-438.
33. Cavalcante P., Bernasconi P., Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 2012, 25:621-629.
34. Gilhus N.E. Myasthenia and the neuromuscular junction. Curr Opin Neurol 2012, 25:523-529.
35. Fambrough D.M., Drachman D.B., Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973, 182:293-295.
36. Engel A.G., Lindstrom J.M., Lambert E.H., Lennon V.A. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology 1977, 27:307-315.
37. Engel A.G., Lambert E.H., Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977, 52:267-280.
38. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005, 57:289-293.
39. Mori S., Kubo S., Akiyoshi T., Yamada S., Miyazaki T., Hotta H., et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012, 180:798-810.
40. Klooster R., Plomp J.J., Huijbers M.G., Niks E.H., Straasheijm K.R., Detmers F.J., et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
41. Harper C.M. Electrodiangosis of endplate diseases. Myasthenia gravis and myasthenic disorders 1999, 65-84. Oxford University Press, New York Oxford. A.G. Engel (Ed.).
42. Slater C.R., Fawcett P.R., Walls T.J., Lyons P.R., Bailey S.J., Beeson D., et al. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain 2006, 129:2061-2076.
43. Slater C.R. Structural factors influencing the efficacy of neuromuscular transmission. Ann N Y Acad Sci 2008, 1132:1-12.
44. Burges J., Vincent A., Molenaar P.C., Newsom-Davis J., Peers C., Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994, 17:1393-1400.
45. Niks E.H., Kuks J.B., Wokke J.H., Veldman H., Bakker E., Verschuuren J.J., et al. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle Nerve 2010, 42:283-288.
46. Viegas S., Jacobson L., Waters P., Cossins J., Jacob S., Leite M.I., et al. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 2012, 234:506-512.
47. Yumoto N., Kim N., Burden S.J. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012, 489:438-442.
48. Wu H., Lu Y., Shen C., Patel N., Gan L., Xiong W.C., et al. Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. Neuron 2012, 75:94-107.
49. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun. Rev 2013, 12(9):924-930. (this issue).
50. Niks E.H., van Leeuwen Y., Leite M.I., Dekker F.W., Wintzen A.R., Wirtz P.W., et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008, 195:151-156.
51. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584.
52. Tsiamalos P., Kordas G., Kokla A., Poulas K., Tzartos S.J. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol 2009, 16:925-930.
53. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 1982, 49:257-265.
54. Tuzon E., Christadoss P. Complement Associated Pathogenic Mechanisms in Myasthenia Gravis. Autoimmun. Rev 2013, 12(9):904-911. (this issue).
55. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
56. Nirula A., Glaser S.M., Kalled S.L., Taylor F.R. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011, 23:119-124.
57. Cole R.N., Ghazanfari N., Ngo S.T., Gervasio O.L., Reddel S.W., Phillips W.D. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010, 588:3217-3229.
58. Mori S., Yamada S., Kubo S., Chen J., Matsuda S., Shudou M., et al. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J Neuroimmunol 2012, 244:1-7.
59. Okada K., Inoue A., Okada M., Murata Y., Kakuta S., Jigami T., et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006, 312:1802-1805.
60. Verschuuren J.G.M., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun. Rev 2013, 12(9):918-923. (this issue).
61. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258.
62. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
63. Dalakas M.C. Novel future therapeutic options in Myasthenia Gravis. Autoimmun. Rev 2013, 12(9):936-941. (this issue).
64. Garcia-Carrasco M., Escarcega R.O., Fuentes-Alexandro S., Riebeling C., Cervera R. Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 2007, 6:373-378.
65. Punga A.R., Flink R., Askmark H., Stalberg E.V. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006, 34:111-115.
66. Punga A.R., Stalberg E. Acetylcholinesterase inhibitors in MG: to be or not to be?. Muscle Nerve 2009, 39:724-728.
67. Punga A.R., Sawada M., Stalberg E.V. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008, 37:300-307.
68. Cartaud A., Strochlic L., Guerra M., Blanchard B., Lambergeon M., Krejci E., et al. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J Cell Biol 2004, 165:505-515.
69. Kawakami Y., Ito M., Hirayama M., Sahashi K., Ohkawara B., Masuda A., et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011, 77:1819-1826.
70. Sanders D.B., Massey J.M., Sanders L.L., Edwards L.J. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000, 54:603-607.
71. Lang B., Pinto A., Giovannini F., Newsom-Davis J., Vincent A. Pathogenic autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 2003, 998:187-195.
72. Pittock S.J., Lucchinetti C.F., Lennon V.A. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003, 53:580-587.
73. Sherratt R.M., Bostock H., Sears T.A. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980, 283:570-572.
74. Thomsen R.H., Wilson D.F. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther 1983, 227:260-265.
75. Wirtz P.W., Verschuuren J.J., van Dijk J.G., de Kam M.L., Schoemaker R.C., van Hasselt J.G., et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009, 86:44-48.
76. Wu Z.Z., Li D.P., Chen S.R., Pan H.L. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J Biol Chem 2009, 284:36453-36461.
77. Mori S., Kishi M., Kubo S., Akiyoshi T., Yamada S., Miyazaki T., et al. 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis. J Neuroimmunol 2012, 245:75-78.